To investigate the clinical implications of BAP1 in ICC, all the 214 ICC patients were dichotomized as BAP1low (scored as negative or weak, n = 115) and BAP1high (scored as moderate or strong, n = 99), according to the immunohistochemical data. Here, BAP1 is linked to intrahepatic cholangiocarcinoma.